Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | ROS1 | P08922 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PRKACA | P17612 | 1/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639783 | 0.80 | GRIA2 (0.38) | PTGS2FFAR4ABL1 | |
| SCHEMBL1640250 | 0.77 | CNR1 (0.38) | CNR1LIPGLIPCFFAR4ABL1 | |
| SCHEMBL1641230 | 0.75 | DYRK3 (0.39) | PTGS2FFAR4ABL1DYRK3ROCK2 | |
| SCHEMBL1641253 | 0.75 | PTGS2 (0.39) | PTGS2FFAR4DYRK3ROCK2PRKD3 | |
| SCHEMBL1713703 | 0.73 | CYP1A2 (0.47) | PTGS2 | |
| SCHEMBL1641419 | 0.73 | PTGS2 (0.40) | PTGS2FFAR4DYRK3ROCK2PRKD3 | |
| SCHEMBL1640249 | 0.73 | KCNH2 (0.39) | PTGS2FFAR4ABL1DYRK3ROCK2 | |
| SCHEMBL1639788 | 0.73 | P2RX3 (0.47) | PTGS2 | |
| SCHEMBL1640275 | 0.72 | PTGS2 (0.36) | PTGS2LIPGLIPCFFAR4CLK2 | |
| SCHEMBL1640405 | 0.72 | HRH3 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273767-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7947711-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090054420-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| US-7456196-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-11-25 | — | — | US | disclosed |
| US-7153889-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | CNR1 15/4885PTGS2 1439/4885LIPG 2758/4885 |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | CNR1 15/4885PTGS2 1439/4885LIPG 2758/4885 |
| US-20090054420-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | CNR1 15/4885PTGS2 1439/4885LIPG 2758/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | CNR1 12/4885PTGS2 1493/4885LIPG 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.